Revolution Medicines, Inc. Common Stock
RVMDRevolution Medicines, Inc. (RVMD) is a biopharmaceutical company focused on developing targeted therapies for genetically driven cancers. The company specializes in designing innovative medicines aimed at specific genetic mutations involved in cancer progression, with an emphasis on solid tumors and hematologic malignancies.
Company News
Ten large-cap stocks surged last week driven by defense spending increases, AI infrastructure deals, and acquisition speculation. Top performers included Regencell Bioscience (89.45% gain), Revolution Medicines (51.38% on Merck acquisition talks), Kratos Defense (36.12% on military budget expansion), AeroVironment (35.86% on Army partnership), Ka...
Merck & Co. is in advanced talks to acquire cancer drug-maker Revolution Medicines for $28-32 billion, marking potentially the largest biotech M&A deal since Pfizer's $43 billion Seagen acquisition in 2023. Revolution Medicines' stock surged 15.14% overnight on the news. The deal reflects Merck's acquisition strategy amid an industry patent cliff...
Revolution Medicines (RVMD) shares tumbled 11.5% in after-hours trading on Wednesday after AbbVie (ABBV) denied reports of acquisition talks. The stock had surged nearly 29% earlier in the day following Wall Street Journal reports that AbbVie was in advanced negotiations to acquire the cancer-drug developer. AbbVie confirmed to Reuters it was not...
Revolution Medicines appointed Alan Sandler, M.D. as chief development officer and added regional general managers in the U.S. and Europe to support potential approvals of RAS-targeted cancer therapies.
Tango Therapeutics' CEO Barbara Weber will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference, presenting a live webcast about the company's precision medicine cancer research.
